Therapeutic agents targeting DNA repair proteins that modify somatic expansion show great potential, with MSH3 as a particularly attractive target for HD and other repeat expansion disorders52, and various MSH3-targeting therapeutics are currently under development53,54. This evidence concerns the gene XRCC6P5 and Huntington disease.